Search
Protirelin
go.drugbank.com/drugs/DB09421ApprovedIt is a tri-peptide tropic hormone, released by the hypothalamus, that stimulates the release of Thyroid Stimulating Hormone (TSH) and prolactin from the anterior pituitary.
Hygromycin B
go.drugbank.com/drugs/DB11520ExperimentalVet approvedHygromycin B is an aminoglycoside antibiotic produced by the bacterium Streptomyces hygroscopicus which kills bacteria, fungi and higher eukaryotic cells by inhibiting protein synthesis.
KC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase.
Dactinomycin
go.drugbank.com/drugs/DB00970ApprovedInvestigationalA compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termina...
Nitroprusside
go.drugbank.com/drugs/DB00325ApprovedInvestigationalNitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing...
Products: DBL SODIUM NITROPRUSSIDE INJECTION 50mg/2mlMidecamycin
go.drugbank.com/drugs/DB13456Investigational[A33075] Until 2017, midecamycin was still under the list of approved antimicrobial active pharmaceutical ingredients by Health Canada.[L2791]
Matrix-M
go.drugbank.com/drugs/DB16369InvestigationalMatrix-M is a saponin-based adjuvant made of nanometer particles, cholesterol, and phospholipid that is developed by Novavax.
Methscopolamine bromide
go.drugbank.com/drugs/DB00462ApprovedA muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Friulimicin B
go.drugbank.com/drugs/DB06087InvestigationalFriulimicin B is a naturally occurring antibiotic produced by a micro-organism, *Actinoplanes friuliensis*.
ALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase